Diabetes patients prescribed GLP-1 receptor agonists had 2-3 times fewer asthma exacerbations compared to those on other diabetes drugs, suggesting GLP-1 drugs may directly benefit airway inflammation.
2-3x fewer asthma attacksGLP-1RA users had 2-3 times fewer asthma exacerbations at 6 months compared to patients on all other diabetes drug classes
What the researchers found
GLP-1RA users had significantly fewer asthma exacerbations at 6 months compared to SGLT-2 inhibitors (IRR 2.98), DPP-4 inhibitors (IRR 2.45), sulfonylureas (IRR 1.83), and basal insulin (IRR 2.58), all with p<0.05.
Why it matters
Asthma affects 300+ million people globally, and those with metabolic conditions often have worse outcomes. GLP-1 drugs could provide dual benefit — treating diabetes while also reducing airway inflammation and asthma attacks.
The numbers in context
448 GLP-1RA; IRR vs GLP-1RA: SGLT2i 2.98, DPP-4i 2.45, SU 1.83, insulin 2.58; asthma symptom visits also lower with GLP-1RA
How the study worked
Retrospective cohort study using electronic health records (2000-2018). New users of GLP-1RA (n=448) compared to SGLT-2i (n=112), DPP-4i (n=435), sulfonylureas (n=2,253), and basal insulin (n=2,692). Propensity score adjustment. Zero-inflated Poisson regression with multiple covariates.
Who was studied
Adults with type 2 diabetes and asthma initiating new diabetes medications
What this study cannot tell us
Retrospective observational study — cannot prove causation. Potential unmeasured confounders. GLP-1RA users may be healthier at baseline despite propensity score adjustment. Single academic healthcare system. Short 6-month follow-up.
How to read the evidence
Moderate evidence: large retrospective cohort with propensity score adjustment and consistent results across all comparators, but observational design cannot establish causation.
When this study was published
Published 2021. Prospective clinical trials investigating GLP-1 drugs specifically for asthma may be underway.
The bigger picture
GLP-1 drugs continue to reveal benefits beyond glucose control. Anti-inflammatory effects in the lungs add to their cardiovascular, renal, and neurological benefits, positioning them as potential multi-organ protective therapies.
Questions still open
- Would GLP-1 agonists reduce asthma attacks in people without diabetes?
- Which specific GLP-1 drug provides the greatest asthma benefit?
- Is the asthma benefit due to anti-inflammatory effects, weight loss, or both?
Common questions
Can GLP-1 drugs like Ozempic help with asthma?
Should I switch my diabetes medication if I have asthma?
Read the original research
Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
American journal of respiratory and critical care medicine, 203(7), 831-840
Citation
Foer, Dinah; Beeler, Patrick E; Cui, Jing; Karlson, Elizabeth W; Bates, David W; Cahill, Katherine N. (2021). Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.. American journal of respiratory and critical care medicine, 203(7), 831-840. https://doi.org/10.1164/rccm.202004-0993OC